PeppiLibrary

Metabolic

Adipotide peptide reference

Pro-apoptotic peptide targeting fat-tissue vasculature. Animal-only weight-loss research.

Last reviewed May 6, 2026 Preclinical Not FDA approved
Peppi reviewing Adipotide notes
Default dose labelNot listed
Preferred routeSubQ (research)
Frequency labelDaily during course (animal protocols)
Storage window21 days mixed

Evidence snapshot

Preclinical

Evidence maturityPreclinical
Animal studies only — primates, rodents, dogs

Research chemical

Route map

How records are usually labeled

1 SubQ
2 IV

Rotate sites.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze long-term.
After mixRefrigerate 2–8 °C, use within 14–21 days.
Use-by cue21 days after mixing
Mixed vial window21 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose Not listed
Route SubQ (research)
Review 21d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Adipotide. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Adipotide (FTPP) is a synthetic chimeric peptide developed at MD Anderson. It pairs a tissue-homing sequence (CKGGRAKDC) that recognises prohibitin in white adipose tissue vasculature with a pro-apoptotic D-(KLAKLAK)2 effector. Animal studies report dramatic reduction of white adipose tissue. No published human clinical data; animal-only safety profile.

Also known as: FTPP, Prohibitin-targeted peptide.

Animal weight-loss researchAdipose vasculature targeting research

Mechanism and timing snapshot

Homing peptide binds prohibitin on white-adipose vasculature; D-amino-acid pro-apoptotic warhead disrupts mitochondrial membrane in associated endothelial cells, ablating fat-tissue vascular supply and inducing fat-cell apoptosis.

Onset labelNot listed
Catalog onset field, when available.
Half-life labelNot listed
Pharmacokinetics in humans not characterised
Duration labelNot listed
Catalog duration field, when available.
subQ Animal studies only
IV Animal studies only

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default doseNot listed
Catalog dose rangeNot listed - Not listed
Default routeSubQ
Frequency labelDaily during course (animal protocols)
Best time labelUnknown for humans.
Food noteUnknown.

Catalog protocol note

Animal protocols use mg/kg dosing for 4 weeks. No validated human protocol.

Routes and site notes

Available route labelsSubQ, IV
Preferred route labelSubQ (research)
Common site labelsAbdomen
Site rotation noteRotate sites.

Chemistry

SequenceCKGGRAKDC-GG-D(KLAKLAK)2
Amino acids23
Molecular formulaNot listed
Molecular weight2611 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size5 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration note5 mg in 2 mL — researchers use mg/kg dosing in animals; human extrapolation not validated.
Before reconstitutionRefrigerate 2–8 °C; freeze long-term.
After reconstitutionRefrigerate 2–8 °C, use within 14–21 days.
Reconstituted shelf life21 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Animal studies: kidney toxicity at higher doses
  • Unknown in humans

Contraindications and warnings

  • Pregnancy
  • Renal impairment
  • Use in humans is generally inadvisable without trial framework
  • No human clinical trial data published.
  • Animal kidney toxicity is a known concern.
  • Pro-apoptotic mechanism — non-specific damage is a real risk if homing fidelity fails.

Other considerations

  • Truly experimental — human safety unknown.
  • Animal weight-loss data is dramatic but kidney toxicity flags caution.
  • GLP-1 family options (semaglutide, tirzepatide) have far better safety records and accomplish weight-loss goals.

Evidence and regulatory context

Evidence levelAnimal studies only — primates, rodents, dogs
FDA approvedNo
Regulatory statusResearch chemical
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteNot listed
Typical cycle label4 (animal protocols)
Typical break labelUnknown
Cycle guidanceNo validated human cycling protocol.

Tracking tips

  • Effectively human-experimental — no published human safety or efficacy data.
  • Renal toxicity in animals is a real flag.
  • GLP-1 agonists offer dramatically better safety profiles for the same weight-loss goal.

References

Track it in Peppi

Keep Adipotide records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Adipotide?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Adipotide?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Adipotide records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026